We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

AnaSpec Introduces new Labeled Antibodies: Anti-CD-3e, Anti-CD79a

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

AnaSpec has introduced a new series of labeled Anti-CD-3e and anti-CD79a antibodies. AnaSpec’s line of Anti-CD-3e, anti-CD79a antibodies are labeled with a range of classic labels like biotin, FAM, and FITC as well as AnaSpec’s proprietary HiLyte Fluor™ labels.

anti-CD-3e:

T cell activation through the T cell antigen receptor (TCR) involves the cytoplasmic tails of the CD3 subunits CD3Y, CD3g, CD3e and CD3d. These CD3 subunits are structurally related members of the immunoglobulins super family encoded by closely linked genes on human chromosome 11. The CD3 components have long cytoplasmic tails that associate with cytoplasmic signal transduction molecules. This association is mediated at least in part by a double tyrosine-based motif present in a single copy in the CD3 subunits. CD3e may play a role in TCR-induced growth arrest, cell survival and proliferation. Rabbit anti-CD3e polyclonal antibody was raised against a synthetic peptide from the human CD3 protein, epsilon chain, only one amino acid different from mouse and rat origins.

anti-CD79a:

The CD79 molecule, comprising two polypeptide chains, mb-1 (CD79a) and B29 (CD79ß), is physically associated in the B-cell membrane with immunoglobulins to constitute the B cell antigen receptor (BCR). The CD79a/ß heterodimer interacts with at least one tyrosine kinase (Lyn). Induction of tyrosine kinase activity after antigen binding causes phosphorylation of the CD79a/ß dimer, and also of other molecules, thereby initiating intracellular signaling. Almost all acute lymphoblastic leukemias of precursor B cell type are positive when tested with CD79a antibodies. Rabbit anti- CD79a polyclonal antibody was raised against a synthetic peptide corresponding to human and mouse CD79a.